Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Causal inference and digital twins: a roadmap for the future of clinical trials.

NPJ digital medicine·2026
Same author

Using Off-Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy Strategy.

Pharmaceutical statistics·2026
Same author

AI-driven reclassification of multiple sclerosis progression.

Nature medicine·2025
Same author

Human bone ultrastructure in 3D: Multimodal correlative study combining nanoscale X-ray computed tomography and quantitative polarized Raman spectroscopy.

Acta biomaterialia·2025
Same author

Why probability probably doesn't exist (but it is useful to act like it does).

Nature·2024
Same author

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same journal

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Personalized prophylactic therapy optimization in hemophilia A using a hybrid PK-PD-TTE model and deep RL.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Pediatric oral cavity physiologically based pharmacokinetic model to predict pharmacokinetics of mucoadhesive atropine gel to treat sialorrhea.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

Combining MCMC with 'sequential' PKPD modelling.

David Lunn1, Nicky Best, David Spiegelhalter

  • 1Medical Research Council Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK. david.lunn@mrc-bsu.cam.ac.uk

Journal of Pharmacokinetics and Pharmacodynamics
|January 10, 2009
PubMed
Summary
This summary is machine-generated.

This study presents a novel method to prevent feedback loops in Bayesian pharmacokinetic-pharmacodynamic (PKPD) models. The approach allows uncertainty in PK parameters to influence PD parameter inference, improving model accuracy.

More Related Videos

A Concoction Pipeline for Generating Molecular Operational Taxonomic Units (MOTUs) Among Riparian and Aquatic Beetles
10:23

A Concoction Pipeline for Generating Molecular Operational Taxonomic Units (MOTUs) Among Riparian and Aquatic Beetles

Published on: July 11, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

A Concoction Pipeline for Generating Molecular Operational Taxonomic Units (MOTUs) Among Riparian and Aquatic Beetles
10:23

A Concoction Pipeline for Generating Molecular Operational Taxonomic Units (MOTUs) Among Riparian and Aquatic Beetles

Published on: July 11, 2025

Area of Science:

  • Pharmacometrics
  • Pharmacokinetics/Pharmacodynamics (PKPD)
  • Statistical Modeling

Background:

  • Bayesian population PKPD models are crucial for drug development.
  • Standard methods often use point estimates, ignoring parameter uncertainty.
  • Unwanted feedback can arise in complex PKPD models, complicating analysis.

Purpose of the Study:

  • To introduce a method for preventing unwanted feedback in Bayesian PKPD link models.
  • To demonstrate the application of this method in general settings, including sequential population models.
  • To highlight the advantage of propagating PK parameter uncertainty to PD parameter inference.

Main Methods:

  • Developed a novel approach to address feedback issues in Bayesian PKPD models.
  • Illustrated the method with a single-individual example.
  • Applied the method to three sequential population PKPD models previously analyzed by Zhang et al.

Main Results:

  • The proposed method effectively prevents unwanted feedback in Bayesian PKPD models.
  • The approach is easily generalizable to complex population models.
  • Uncertainty in PK parameters is successfully propagated to PD parameter inferences.

Conclusions:

  • The new method offers an improvement over standard two-stage approaches by incorporating parameter uncertainty.
  • This approach enhances the reliability of inferences in PKPD modeling.
  • Graphical representations aid in understanding the structure of complex PKPD models.